06.06.2024 14:47:50 - dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
ABBVIE INC. DL-,01 A1J84E Frankfurt 157,520 27.06.24 17:55:44 -3,440 -2,14% 157,020 157,500 159,020 160,960

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH